Bioinspired Healing

Deep techBioinspired biointerfacesICN2 – CSIC spin-off

Bioinspired medical polymers fighting chronic and fatal diseases

Tirecat Health develops bioinspired medical polymers: adhesive membranes that act as biointerfaces, sticking to wet tissue, fighting infection without antibiotics and driving regeneration. Our first product, RESKIN, targets infected chronic wounds, starting with diabetic foot ulcer, with a first-in-human study planned for 2027.

RESKIN bioinspired membrane
RESKINLead product · TRL 6
−95% infectionPreclinical · vs control
FIH 2027Diabetic foot ulcer

Backed by

Our purpose

To fight chronic and fatal diseases by improving the quality of life of life-long patients.

Chronic diseases such as diabetes leave millions of people with wounds and tissue damage that do not heal. We want to change their lives.

Our mission

To develop, manufacture and distribute bioinspired adhesive membranes: biointerfaces that revolutionise regenerative medicine worldwide.

Inspired by nature, our membranes interact with living tissue in a new way: they adhere, protect against infection and help the body repair itself.

Where we are in 2026

Our lead clinical indication: chronic wounds (diabetic foot ulcers)

Our platform can address several chronic diseases. For now, we have chosen chronic wounds, starting with diabetic foot ulcers, as our first clinical indication.

− 0 %

fewer infections vs control (3% vs 58%) in an infected porcine wound model

− 0 %

time to full wound closure (13 vs 22 days)

2020

first-in-human feasibility study (planned)

The problem

Three crises converging on one wound

Chronic wounds

More than 26 million people in Europe and the USA live with a chronic wound. One in four people with diabetes will develop a foot ulcer, and many face amputation.

Antimicrobial resistance

Resistant bacteria colonise most chronic wound beds. Antimicrobial resistance already causes around 700,000 deaths a year and is one of the WHO’s top global health threats.

A structural gap

Today’s products do one job: they adhere, or fight bacteria, or support regeneration. None combines all of these in a single, affordable product.

Our solution

RESKIN: one membrane, four functions, no drugs

Bioadhesive

Adheres to wet tissue without sutures, staples or negative-pressure systems, inspired by mussel adhesive proteins.

Antimicrobial

Kills bacteria on contact through reactive oxygen species, without antibiotics. Active against resistant strains in preclinical studies.

Regenerative

A nano-structured scaffold that supports cell migration, proliferation and the growth of new blood vessels.

Biocompatible and biodegradable

Gradually absorbed while the wound heals: one application, no removal, no added trauma.

Membrane sheet

The RESKIN membrane: thin, flexible and ready to use.

Fibroblasts in the membrane

Skin cells (fibroblasts) growing on the membrane.

Made in a single step, in water and at room temperature: a simple, scalable and low-cost process. Watch the material in action →

Institutional partners and shareholders

Born from public research, backed by its institutions

Tirecat Health is a spin-off of the Catalan Institute of Nanoscience and Nanotechnology (ICN2) and the Spanish National Research Council (CSIC), the two institutions that own the RESKIN patents and are shareholders of the company, together with Criteria Capital Risc, of the “la Caixa” group.

Part of this work was funded by the Spanish Ministry of Science, Innovation and Universities (Proof of Concept project), with NextGenerationEU funds.

Let’s work together

How can we collaborate?

Clinicians

Help us shape the first clinical studies and future indications of RESKIN.

Industry partners

Licensing, co-development and new applications of our bioinspired platform.

Investors

Back a deep-tech company on its way to first-in-human in 2027.

RESKIN is an investigational medical device. It is not available for sale.